Funding Acknowledgements Type of funding sources: None. Background/Introduction Steerable sheaths are frequently used to improve catheter contact during pulmonary vein isolation (PVI) procedures. A new type of visualized (by electroanatomical mapping system) steerable sheath has become available in clinical treatment. Purpose We aimed to compare procedural data of visualizable vs. non-visualizable steerable sheath assisted PVI procedures of patients with atrial fibrillation (AF). Methods In this single-center randomized study, we enrolled a total of 58 consecutive patients who underwent PVI due to AF. In 30 patients, the procedures were performed using non-visualizable steerable sheath (Group 1), while we used visualizable steerable sheath for PVI in 28 cases (Group 2). Results Compared to Group 1, using the visualizable sheath significantly reduced total fluoroscopy time (267 ± 145 s vs. 197 ± 74 s; p=0.03), fluoroscopy dose (26.2 ± 24.7 mGy vs. 16.7 ± 16.1 mGy; p=0.04) and left atrial procedure time (72.1 ± 18.7 min vs. 61.4 ± 18.9 min; p=0.05). Total ablation time (1158 ± 347 s vs. 1067 ± 196 s; p= 0.28), number of radiofrequency pulses (78 ± 19 vs. 77 ± 32; p=0.81) and total procedure time (117.7 ± 30.0 min vs. 105.0 ± 21.4 min; 0.09) did not differ between the two groups. No major complications occurred in either group. Conclusion Using visualizable steerable sheath for PVI procedures can reduce fluoroscopy exposure and left atrial procedure time compared to standard, non-visualizable steerable sheath in patients undergoing PVI procedures.
Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): ÚNKP-22-4 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund. Steerable sheaths (SSs) are frequently used to improve catheter stability during atrial fibrillation (AF) procedures. A new type of visualizable (by electroanatomical mapping system) SS has become available in clinical treatment. Purpose We aimed to compare procedural and follow up data of visualizable vs. non-visualizable SS assisted pulmonary vein isolation procedures in patients with AF. Methods In this single-centre randomized study, we enrolled a total of 100 consecutive patients who underwent PVI due to AF. Results 100 consecutive patients were enrolled and randomized into 2 groups (visualizable SS group: 50; non-visualizable SS group: 50). With the use of visualizable SS, left atrial (LA) procedure time (53.1 [41.3; 73.1] min vs. 59.5 [47.6; 74.1] min.; p = 0.04), LA fluoroscopy time (0 [0; 0] s vs. 17.5 [5.5; 69.25] s; p < 0.01) and LA fluoroscopy dose (0 [0; 0.27] mGy vs. 0.74 [0.16; 2.34] mGy; p < 0.01) was significantly less, however, there was no difference in the total procedural time (90 ± 35.2 min vs. 99.5 ± 31.8 min; p = 0.13), total fluoroscopy time (184 ± 89 s vs. 193 ± 44 s; p = 0.79), and total fluoroscopy dose (9.12 ± 1.98 mGy vs. 9.97 ± 2.27 mGy; p = 0.76). Compared to standard SS group total ablation time was reduced (1049 sec. [853; 1175] vs. 1265 sec. [1085; 1441]; p < 0.01) using visualizable SS, and the number of radiofrequency ablations was fewer (69 [58; 80] vs. 79 [73; 86); p < 0.01) in this group. There was no difference between the groups regarding acute ablation success (both group 100%) and first pass isolation rate (92% vs. 89%; p = 0.88). No major complications occurred in either group. During the 6 months follow up period there was no difference either in blanking period (visulaizable SS: 3/50, standard SS: 4/50; p=0.70) or at 6 months after the ablation (visulaizable SS: 3/50, standard SS: 5/50; p=0.46). Conclusion Visualizable SS significantly can reduce the left atrial procedure time, total ablation time and fluoroscopy exposure without compromising its safety or mid-term success in patients undergoing PVI procedures for AF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.